Protagonist Therapeutics (PTGX) Non-Current Assets (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Non-Current Assets data on file, last reported at $84.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 38.36% year-over-year to $84.0 million; the trailing twelve-month figure through Mar 2026 stood at $451.0 million (up 46.06% YoY), and the FY2025 full-year result was $11.7 million, down 7.28% from the prior year.
• Non-Current Assets improved to $84.0 million in Q1 2026, from $11.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $136.3 million in Q1 2025 to a low of $1.7 million in Q1 2024.
• A 5-year average of $40.3 million and a median of $6.8 million in 2022 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets sank 87.78% in 2022 and surged 7809.0% in 2025, its largest moves.
• Tracing PTGX's Non-Current Assets over 5 years: stood at $4.6 million in 2022, then slumped by 53.55% to $2.1 million in 2023, then soared by 486.64% to $12.6 million in 2024, then fell by 7.28% to $11.7 million in 2025, then jumped by 618.66% to $84.0 million in 2026.
• Business Quant data shows PTGX's Non-Current Assets at $84.0 million in Q1 2026, $11.7 million in Q4 2025, and $115.3 million in Q3 2025.